Chidamide Plus R-CHOP in Elderly DLBCL
This is a prospective, single-arm, open-label phase II study of Chidamide in combination with R-CHOP in the treatment of de novo, elderly, high-risk diffuse large B cell lymphoma patients.
Diffuse Large B-cell Lymphoma
DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DRUG: Chidamide
Complete response rate, 21 days after 6 cycles of treatment (each cycle is 21 days)
Progression free survival rate, 2 year|Overall survival rate, 2 year|Overall response rate, 21 days after 6 cycles of treatment (each cycle is 21 days)|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Each cycle of treatment and then every 3 months for 2 years
This is a prospective, single-arm, open-label phase II study of Chidamide in combination with R-CHOP in the treatment of de novo, elderly, high-risk diffuse large B cell lymphoma patients.